CymaBay Announces Participation at Three Upcoming Investor Conferences

Download as PDF

NEWARK, Calif., Nov. 13, 2015 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced that management will participate in three upcoming healthcare investor conferences in November and December.

Stifel 2015 Healthcare Conference
Date: Tuesday, November 17, 2015
Presentation Time:     5:10pm Eastern Time
Location: The New York Palace Hotel
Webcast: http://ir.cymabay.com/events
   
Jefferies Autumn 2015 Global Healthcare Conference
Date: Wednesday and Thursday, November 18-19, 2015
Location: May Fair Hotel, London, UK
   
Piper Jaffray 27th Annual Healthcare Conference
Date: Tuesday, December 1, 2015
Presentation Time: 4:00pm Eastern Time
Location: The New York Palace Hotel
Webcast: http://ir.cymabay.com/events

About CymaBay

CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate, has shown two therapeutic actions in a single drug in multiple Phase 2 gout studies. In gout patients, arhalofenate is intended to prevent painful flares in joints while at the same time promoting excretion of uric acid by the kidney, thereby addressing both the signs and symptoms of gout and the hyperuricemia that is the root cause of the disease. MBX-8025 is a potent, selective, orally active PPARδ agonist. A Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has two ongoing clinical studies for MBX-8025 including a pilot Phase 2 study in patients with homozygous familial hypercholesterolemia and a Phase 2 study in patients with primary biliary cholangitis.

For additional information about CymaBay visit www.cymabay.com.

CONTACT: Sujal Shah
         CymaBay Therapeutics, Inc.
         (510) 293-8800
         Investors@CymaBay.com

         Hans Vitzthum
         LifeSci Advisors, LLC
         212-915-2568
         Hans@LifeSciAdvisors.com
Source: CymaBay Therapeutics, Inc.

Released November 13, 2015